Lophophine
Lophophine, also known as 2C-MMDA-1, 5-methoxy-MDPEA, or 3-methoxy-4,5-methylenedioxyphenethylamine, is a psychedelic drug of the methylenedioxyphenethylamine family. It is the α-demethylated homologue of MMDA, and is also closely related to mescaline and MDPEA. Lophophine has been encountered as a novel designer drug.
Use and effects
Alexander Shulgin reported in his publications that lophophine is active in the dose range of 150 to 250mg orally. He states that at these doses, lophophine has some similarity to mescaline in action, in producing a peaceful elevation of mood, euphoria, and mild enhancement of visual perception, but without the generation of closed-eye mental imagery. Shulgin also notes that, in contrast to mescaline, lophophine causes no nausea. He estimated that it was about twice the potency of mescaline.
Chemistry
Lophophine, also known as 3-methoxy-4,5-methylenedioxyphenethylamine, is a phenethylamine and methylenedioxyphenethylamine derivative.
Synthesis
The chemical synthesis of lophophine has been described.
Analogues
Analogues of lophophine include mescaline, 3,4-methylenedioxyphenethylamine, 2C-MMDA-2, 2C-MMDA-3a, and MMDA, among others.
Alexander Shulgin originally suggested that lophophine may be a natural constituent of peyote due to it being the only logical chemical intermediate for the biosynthesis of several tetrahydroisoquinolines known to be present in this cactus species. Subsequently, lophophine was indeed shown to be a minor component of both peyote and San Pedro cactus.
History
Lophophine was encountered as a novel designer drug in Europe in 2023.
Legal status
Canada
Lophophine is controlled substance in Canada under phenethylamine blanket-ban language.
United States
Lophophine is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.